visceral fat raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-11. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
纯度与身份确认依赖色谱与质谱的组合。反相高效液相色谱在 214 nm 紫外检测下分离主峰与相关杂质，给出纯度百分比与保留时间；电喷雾或基质辅助激光解吸电离质谱提供分子量，用于确认 N 端修饰是否完整。序列层面可通过肽图或氨基酸分析验证。含量测定常用紫外吸收法或氮元素分析，不同方法之间需要做交叉校验。
冻干粉末一般在 -20°C 或更低温度、干燥避光条件下保存，可维持较长时间的稳定。复溶后稳定性明显下降，溶液中的肽链易发生水解、氧化与聚集，通常需冷藏并在短期内用完。反复冻融会加速聚集与降解，建议分装后单次使用。缓冲体系的 pH 与离子强度同样影响聚集速率，需要按具体实验条件验证。
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
=== Ferromagnetic and ferroelectric effects === The small size of nanoparticles affects their magnetic and electric properties. The ferromagnetic materials in the micrometer range is a good example: widely used in magnetic recording media, for the stability of their magnetization state, those particles smaller than 10 nm are unstable and can change their state (flip) as the result of thermal energy at ordinary temperatures, thus making them unsuitable for that application.
However the secondary meaning of Basque gibel is "indolence". In biblical Hebrew, the word for liver, כבד (Kauved, stemmed KBD or KVD, similar to Arabic الكبد), also means heavy and is used to describe the rich ("heavy" with possessions) and honor (presumably for the same reason). In the Book of Lamentations (2:11) it is used to describe the physiological responses to sadness by "my liver spilled to earth" along with the flow of tears and the overturning in bitterness of the intestines. On several occasions in the book of Psalms (most notably 16:9), the word is used to describe happiness in the liver, along with the heart (which beats rapidly) and the flesh (which appears red under the skin). Further usage as the self (similar to "your honor") is widely available throughout the old testament, sometimes compared to the breathing soul (Genesis 49:6, Psalms 7:6, etc.). An honorable hat was also referred to with this word (Job 19:9, etc.) and under that definition appears many times along with פאר Pe'er - grandeur. These four meanings were used in preceding ancient Afro-Asiatic languages such as Akkadian and Ancient Egyptian preserved in classical Ethiopic Ge'ez language. Anatomical and medical terminology often use the prefix hepat- from ἡπατο-, from the Greek word for liver, such as hepatology, and hepatitis
== Portraits == The National Portrait Gallery, London lists 17 portraits of Dorothy Hodgkin including an oil painting of her at her desk by Maggi Hambling and a photograph portrait by David Montgomery. Graham Sutherland made preliminary sketches for a portrait of Dorothy Crowfoot Hodgkin in 1978. One sketch is in the collection of the Science History Institute and another at the Royal Society in London. The portrait was never finished. A portrait of Dorothy Hodgkin by Bryan Organ was commissioned by private subscription to become part of the collection of the Royal Society. Accepted by the president of the society on 25 March 1982, it was the first portrait of a woman Fellow to be included in the Society's collection.
Sources: en.wikipedia.org
Sinecatechins (Veregen) was the first botanical drug approved in the US in 2006; a green tea extract, for genital warts Crofelemer (Mytesi), approved by the FDA in 2012, an extract of "dragon's blood" sap of the Croton lechleri plant, for diarrhea in people with HIV/AIDS Nabiximols (USAN, trade name Sativex) is a specific extract of Cannabis approved as a botanical drug in the United Kingdom as a mouth spray for people with multiple sclerosis, who can use it to alleviate neuropathic pain, spasticity, overactive bladder, and other symptoms; it was developed by the UK company GW Pharmaceuticals Menerba is a botanical drug candidate consisting of 22 herbs that have been used historically in traditional Chinese medicine that act as a selective estrogen receptor modulator. As of 2015 the FDA had approved Bionovo's chemical manufacturing and controls and Menerba was in a Phase III clinical trial as a potential treatment to relieve hot flashes associated with menopause.
=== Biotechnology === Industrial biotechnology, also called "white biotechnology", is increasingly impacting the chemical industry, enabling both the conversion of renewable resources, such as sugar or vegetable oils, and the more efficient transformation of conventional raw materials into a wide range of commodities (such as cellulose, ethanol and succinic acid), fine chemicals (such as 6-aminopenicillanic acid), and specialties (such as food and feed additives). As opposed to green and red biotechnology, which relate to agriculture and medicine, respectively, white biotechnology seeks to improve the economic and sustainable production of existing products, and provide access to new products, especially biopharmaceuticals. It is expected that revenues from white biotechnology will account for 10%, or $250 billion, of the global chemical market of $2,500 billion by 2013. In ten to 15 years, it is expected that most amino acids and vitamins and many specialty chemicals will be produced by means of biotechnology. Three very different process technologies — biocatalysis, biosynthesis (microbial fermentation), and cell cultures — are used. Biocatalysis, also known as biotransformation or bioconversion, makes use of natural or modified isolated enzymes, enzyme extracts, or whole-cell systems for enhancing the production of small molecules. It has much to offer compared to traditional organic synthesis. The syntheses are shorter, less energy intensive and generate less waste, and are thus both environmentally and economically more attractive.
Clobazam, sold under the brand names Frisium and Onfi, among others, is a long-acting benzodiazepine medication primarily used as an anxiolytic and anticonvulsant. Clobazam is a 1,5-benzodiazepine with unique pharmacological characteristics that was patented in 1968. Clobazam was first synthesized in 1966 and first published in 1969. It was approved in Australia in 1970 and France in 1974 for short-term anxiety management. Clobazam is solely approved for use in the United States as a treatment for Lennox–Gastaut syndrome, but the drug is available in other countries as an anti-anxiety agent for the short-term treatment of persistent and debilitating forms of anxiety. It has shown a distinct profile and addictive potential compared to the more common benzodiazepines. Clobazam is the only 1,5‑benzodiazepine that has been marketed for clinical use, making it the sole representative of this structural class of benzodiazepines. The drug has been approved by Health Canada as an add-on therapy for generalized tonic–clonic, myoclonic, and focal impaired awareness seizures. In 2011, Lundbeck markets the drug in the United States as Onfi, an adjunctive therapy for seizures associated with Lennox–Gastaut syndrome in patients who are at least two years old.
Sources: en.wikipedia.org
In 1857, the American Watch Company in Waltham, Massachusetts, introduced the Waltham Model 57, the first to use interchangeable parts. This cut the cost of manufacture and repair. Most Model 57 pocket watches were in a coin silver ("one nine fine"), a 90% pure silver alloy commonly used in dollar coinage, slightly less pure than the British (92.5%) sterling silver, both of which avoided the higher purity of other types of silver to make circulating coins and other utilitarian silver objects last longer with heavy use.
Merigolix (INNTooltip International Nonproprietary Name; developmental code names HS-10518, NCE-403, SKI-2670, TU-2670) is a gonadotropin releasing hormone (GnRH) antagonist which is under development for the treatment of endometriosis and uterine fibroids. It is taken by mouth. The drug is being developed by TiumBio, Daewon Pharmaceutical, and Jiangsu Hansoh Pharmaceutical. As of October 2024, it is in phase 2 clinical trials for both endometriosis and uterine fibroids.
This is a bibliography of works by Oscar Wilde (1854–1900), a late-Victorian Irish writer. Chiefly remembered today as a playwright, especially for The Importance of Being Earnest, and as the author of The Picture of Dorian Gray; Wilde's oeuvre includes criticism, poetry, children's fiction, and a large selection of reviews, lectures and journalism. His private correspondence has also been published. Wilde was declared bankrupt to pay legal costs after his conviction for "gross indecency," and his possessions – including manuscripts, letters, books and presentation volumes of all the major literary figures of his day – were sold by auction. This has made bibliographical (and biographical) studies of unpublished work more difficult since they are widely dispersed, some in private ownership. The largest collection of Wilde's letters, manuscripts, and other material relating to his literary circle are housed at the William Andrews Clark Memorial Library. A number of Wilde's letters and manuscripts can also be found at the British Library, as well as public and private collections throughout Britain, the United States and France.
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.